Literature DB >> 25989738

[Therapeutic options for brain metastases].

M Preusser1, F Winkler.   

Abstract

Brain metastases are common in cancer patients, especially in lung cancer, breast cancer and melanoma and represent a therapeutic challenge. Established local therapeutic procedures include neurosurgical resection, stereotactic irradiation and whole brain radiotherapy; however, for selected patients novel targeted therapies with documented activity against brain metastases are emerging. These include v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors, the anticytotoxic T lymphocyte-associated protein 4 (CTL4A) antibodies ipilimumab in melanoma, HER2 antagonists in breast cancer and epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer. Therefore, the modern management of patients with brain metastases should be performed in an interdisciplinary setting and under consideration of relevant molecular markers to facilitate optimal patient outcome.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25989738     DOI: 10.1007/s00115-015-4278-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  14 in total

1.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

2.  Breast cancer brain metastases responding to primary systemic therapy with T-DM1.

Authors:  Rupert Bartsch; Anna S Berghoff; Matthias Preusser
Journal:  J Neurooncol       Date:  2013-09-25       Impact factor: 4.130

3.  Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases.

Authors:  Sofia Torres; Pejman Maralani; Sunil Verma
Journal:  BMJ Case Rep       Date:  2014-08-14

Review 4.  Brain metastases: pathobiology and emerging targeted therapies.

Authors:  Matthias Preusser; David Capper; Aysegül Ilhan-Mutlu; Anna Sophie Berghoff; Peter Birner; Rupert Bartsch; Christine Marosi; Christoph Zielinski; Minesh P Mehta; Frank Winkler; Wolfgang Wick; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2012-01-03       Impact factor: 17.088

5.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

6.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

Authors:  Kim Margolin; Marc S Ernstoff; Omid Hamid; Donald Lawrence; David McDermott; Igor Puzanov; Jedd D Wolchok; Joseph I Clark; Mario Sznol; Theodore F Logan; Jon Richards; Tracy Michener; Agnes Balogh; Kevin N Heller; F Stephen Hodi
Journal:  Lancet Oncol       Date:  2012-03-27       Impact factor: 41.316

Review 7.  CNS metastases in breast cancer: old challenge, new frontiers.

Authors:  Nancy U Lin; Laleh Amiri-Kordestani; Diane Palmieri; David J Liewehr; Patricia S Steeg
Journal:  Clin Cancer Res       Date:  2013-12-01       Impact factor: 12.531

8.  Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.

Authors:  Paul W Sperduto; Samuel T Chao; Penny K Sneed; Xianghua Luo; John Suh; David Roberge; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen Shih; John Kirkpatrick; Amanda Schwer; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan Knisely; Christina Maria Sperduto; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-26       Impact factor: 7.038

9.  Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.

Authors:  Mary W F Azer; Alexander M Menzies; Lauren E Haydu; Richard F Kefford; Georgina V Long
Journal:  Cancer       Date:  2013-11-05       Impact factor: 6.860

10.  EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data.

Authors:  Yun Fan; Xiaoling Xu; Conghua Xie
Journal:  Onco Targets Ther       Date:  2014-11-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.